Close

Synthetic Biologics (SYN) Reports Positive Topline Results from Phase 1a Trial of SYN-004

December 22, 2014 7:16 AM EST Send to a Friend
Synthetic Biologics, Inc. (NYSE: SYN) today announced positive topline safety and tolerability results from a Phase 1a clinical trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login